Avalor Therapeutics

Biotechnology Innovation

StageSeed

Raised$335K - $340K

Employees2

LocationKenmore, WA

About

Avalor Tx is a startup biotech company focused on developing breakthrough disease-modifying medicines for significant unmet medical needs that are driven by chronic inflammation and that are life-threatening and/or impose painful disability on patients.

Product

Value proposition: Developing breakthrough therapeutics focused on patient needs through rigorous scientific excellence and teamwork.

Founders

Will Martinez — Co-Founder and CEO
Ken Wild — Co-Founder

Key features

Patient-focused unmet-need drivenIntegrity and scientific excellenceTeam above selfHumility and persistence

Investors

New Leaf Venture PartnersSignite PartnersHana Financial GroupGGV Capital

News

Avalo Therapeutics · 2025-07-14T00:00:00.000Z
Avalo scores Phase 2 success in comeback bid, raises $375M · 2026-05-06T15:00:17.000Z
Avalo Therapeutics Announces Pricing of $375 Million Public Offering - BioSpace · 2026-05-06T06:17:08.000Z
Avalo Therapeutics Reports First Quarter 2026 Financial · 2026-05-13T11:00:00.000Z
Avalo Prices $375M Offering Following Strong Phase 2 Abdakibart Data; Stock Up · 2026-05-06T08:16:39.000Z
Cerecor Rebrands to Avalo Therapeutics | BioBuzz · 2024-12-02T21:42:48.000Z